The mortality rate due to breast cancer has declined over the preceding decades to a great extent, secondary to the development and use of effective adjuvant therapy. Tamoxifen remains the standard of care in premenopausal women, whereas aromatase inhibitors have become standard therapy after menopause for women with hormone-sensitive disease. Tumor gene profiling assays are being increasingly used to identify women with hormone-sensitive disease, who would benefit from adjuvant chemotherapy. For those women with hormone negative cancer, systemic chemotherapy provides substantial reduction in the risk of disease recurrence and death.
*Medical Oncology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island; and
†The Center for Sexuality, Intimacy, and Fertility, Program in Women's Oncology, Women & Infants' Hospital and The Warren Alpert Medical School of Brown University, Providence, Rhode Island
Correspondence: Bachir J. Sakr, MD, Program in Women's Oncology, Women and Infants’ Hospital of Rhode Island, Providence, RI. e-mail: email@example.com